BDXA Q2 2026 Earnings Call Summary

BD (BDXA) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $4.7 billion, up 2.6% year-over-year (FX-neutral).
Adjusted Operating Margin: 24.2%, down 110 basis points from the prior year.
Adjusted EPS: $2.90, up 3.9%, exceeding expectations.
Free Cash Flow: $1.1 billion year-to-date, significantly improved due to better working capital management.
Shareholder Returns: $2.3 billion returned, including $2 billion in share repurchases.

2. Strategic Updates and Business Highlights

Leadership Change: Vitor Roque appointed as CFO, previously Interim CFO, emphasizing continuity and focus on execution.
New BD Strategy: Focus on three priorities: compete, innovate, and deliver. Over 90% of the portfolio showed mid-single-digit growth.
Growth Platforms: Double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration.
Operational Excellence: Continued implementation of BD Excellence, driving productivity gains of 8% in Q2 and improving service levels.
Cost Management: Progress on a $200 million cost-out program, with $150 million already achieved.

3. Forward Guidance and Outlook

Full-Year Revenue Guidance: Reaffirmed low single-digit growth, with second-half growth expected to mirror the first half.
Adjusted EPS Guidance: Increased to $12.52 to $12.72, reflecting strong first-half performance and productivity improvements.
Market Dynamics: Anticipated currency tailwind of approximately 120 basis points for revenue.

4. Bad News, Challenges, or Points of Concern

Headwinds: Ongoing pressures from Alaris, vaccines, and market dynamics in China, which collectively represent less than 10% of revenue.
FDA Warning Letter: Received for the El Paso facility affecting ChloraPrep and PurPrep products, leading to a temporary shipping hold while additional testing is conducted.
Margin Pressures: Adjusted gross margin down 90 basis points due to tariffs and increased commercial investments.

5. Notable Q&A Insights

Alaris Business: Expected to contribute a 200 basis point headwind in FY 2027, with a return to mid-single-digit growth anticipated in FY 2028.
GLP-1 Market: Continued optimism despite potential competition from oral GLP-1s; BD's strong position in biologics and biosimilars remains a focus.
Capital Allocation: Emphasis on share repurchases over tuck-in M&A due to perceived undervaluation of the company, while remaining disciplined in future acquisitions.
Operational Strategy: BD Excellence is being applied to R&D and commercial processes, aiming to enhance efficiency and speed to market for new products.

Overall, BD demonstrated solid performance in Q2 2026, with strong revenue growth and operational execution, while navigating specific challenges in certain segments and maintaining a positive outlook for the remainder of the fiscal year.

BDXA — Becton, Dickinson and Company